Sign in
4

Changes in Ownership

BioXcel Therapeutics, Inc. Filed Acc 0001104659-24-129462

CEO and President sold 3,117 shares at an average $0.36 ($1,131)

  • CEO and President acquired 6,110 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Mehta Vimal · CEO and President

Table I: Non-derivative

4 lines
Date Transaction Shares Price Value Owned after D/I
2024-12-14 Exercise or conversion : show line 1 in the form 10b5-1 +2,610 58,403 D
2024-12-15 Exercise or conversion : show line 2 in the form 10b5-1 +3,500 61,903 D
2024-12-16 Sale : show line 3 in the form 10b5-1 −983 $0.36 $358 60,920 D
2024-12-16 Sale : show line 4 in the form 10b5-1 −2,134 $0.36 $773 59,605 D
Open-market sales · 3,117 sh · avg $0.36 · $1,131

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2024-12-14 Exercise or conversion : show line 5 in the form 10b5-1 Restricted Stock Units −2,610 13,049 D
2024-12-15 Exercise or conversion : show line 6 in the form 10b5-1 Restricted Stock Units −3,500 31,500 D
Loading xslF345X05/tm2431371-4_4seq1.xml…